Summary

for people ages 18 years and up (full criteria)
at UCSF
study started
estimated completion

Description

Summary

This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.

Official Title

The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension

Keywords

Glaucoma, Open-Angle Ocular Hypertension Glaucoma Hypertension Timolol Bimatoprost Bimatoprost sustained-release Bimatoprost SR Dose A Bimatoprost SR Dose B

Eligibility

You can join if…

Open to people ages 18 years and up

  • Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes require IOP-lowering treatment.

You CAN'T join if...

  • Previous enrollment in another Allergan Bimatoprost SR Study
  • Eye surgery (including cataract surgery) and/or any eye laser surgery within the past 6 months in the study eye
  • Anticipated need for laser eye surgery within the first 52 weeks of the study duration
  • History of glaucoma surgery

Locations

  • University of California San Francisco
    San Francisco California 94143 United States
  • Eye Research Foundation
    Newport Beach California 92663 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Allergan
Links
More Information
ID
NCT02250651
Phase
Phase 3
Study Type
Interventional
Last Updated